Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

Inclusion Criteria:

• Histologically confirmed mucinous carcinoma of the ovary or fallopian tube

  • Cytological (e.g., fine-needle aspiration) examination is inadequate for diagnosis
  • No epithelial non-mucinous cell types

• Meets 1 of the following staging criteria:

  • FIGO stage II-IV disease
  • Recurrent stage I disease (chemonaïve)
• Patients must have a negative colonoscopy within 1 year before study entry
• No primary peritoneal carcinoma
• No epithelial ovarian tumors of low malignant potential
• No known brain metastases
• ECOG performance status 0-2
• Life expectancy > 3 months
• WBC ≥ 3 x 10^9/L
• Absolute neutrophil count ≥ 1.5 x 10^9/L
• Platelet count ≥ 100 x 10^9/L
• Hemoglobin ≥ 10 g/dL (may be post-transfusion)
• Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
• Serum transaminases ≤ 2.5 x ULN
• Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 50 mL/min
• Urine dipstick for proteinuria < 2+ OR 24-hour urine protein ≤ 1 g
• INR ≤ 1.5 x ULN
• APTT ≤ 1.5 x ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

• Adequate neurological function (sensory and motor neuropathy ≤ grade 1)

  • No prior or concurrent peripheral neuropathy
• No evidence of upper GI cancer (e.g., pancreatic cancer) on CT or MRI scan
• No history of another malignancy except carcinoma in situ of the cervix or basal cell carcinoma of the skin
• No medical or psychiatric conditions that compromise the patient's ability to give informed consent
• No clinically significant cardiac disease, symptomatic coronary artery disease, or congestive heart failure
• No peripheral vascular disease ≥ grade 3 (i.e., symptomatic and interfering with activities of daily living requiring repair or revision), cardiac arrhythmia, or myocardial infarction within the past 12 months
• No known hypersensitivity to bevacizumab and its excipients or to chemotherapy (including cremophor)
• No history of malabsorption or other conditions preventing oral treatment
• No nonhealing wound, ulcer, or bone fracture (patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible provided they undergo three weekly wound examinations)
• No history or evidence of thrombotic or hemorrhagic disorders
• No uncontrolled hypertension (sustained elevation of BP > 150/100 mmHg despite antihypertensive therapy)
• No significant traumatic injury within the past 4 weeks
• No cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage within the past 6 months
• No other concurrent uncontrolled medical conditions
• No prior chemotherapy
• No prior radiotherapy or investigational treatment for ovarian or rectal cancer
• No prior mouse CA125 antibody

• At least 10 days since prior and no concurrent chronic use of aspirin (> 325 mg/day)

  • Prophylactic low-dose aspirin (≤ 325 mg/day) in patients who are at risk of an arterial thromboembolic event allowed

• At least 4 weeks since prior surgery or open biopsy and no planned surgery during the 58-week period from the start of study treatment

  • No second-look surgery